[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-heart-failure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100612357","european-study-of-the-briovad-heart-pump-for-advanced-heart-failure-100612357",false,"NCT07252531","European Study of the BrioVAD Heart Pump for Advanced Heart Failure","European Investigation of the BrioVAD Left Ventricular Assist System for the Treatment of Refractory Left Ventricular Heart Failure","BRIOLIFE","INCLUSION CRITERIA:\n\n1. Patient is ≥ 18 years of age.\n2. Patient has a body surface area (BSA) ≥ 1.2 m2.\n3. Patient is classified as NYHA Class IV with advanced heart failure refractory to advanced heart failure management or NYHA Class III with dyspnea upon mild physical activity.\n4. Patient has a left ventricular ejection fraction (LVEF) ≤ 25% or LVEF \\\u003C 30% on inotropes or intra-aortic balloon pump (IABP).\n5. Patient is inotrope dependent, OR has a cardiac index (CI) ≤ 2.2 liters\u002Fmin\u002Fm2, while not on inotropes, and also meets one of the following criteria:\n\n   1. Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or\n   2. Has advanced heart failure for at least 14 days and is dependent on an IABP for at least seven days.\n6. Patient has provided voluntary and informed consent.\n7. Females of childbearing age agree to use adequate contraception and have a negative pregnancy test.\n\nEXCLUSION CRITERIA:\n\n1. Patient's heart failure etiology is related to restrictive or constrictive physiology (e.g., nondilated hypertrophic cardiomyopathy, cardiac amyloidosis\u002Fsenile or other infiltrative disease), complex congenital heart disease (e.g., transposition of the great vessels), uncorrected thyroid disease, and\u002For pericardial disease.\n2. Patient had a myocardial infarction within seven days before study enrollment.\n3. Patient had cardiothoracic surgery within 30 days before implant.\n4. Patient has physiological conditions or comorbidities which pose high surgical risk or obstacles as determined by the Investigator.\n5. Patient has contraindications to warfarin anticoagulation.\n6. Patient has known hypo- or hypercoagulable state \\[e.g., disseminated intravascular coagulation (DIC)\\], or has a positive heparin-induced thrombocytopenia (HIT) assay and positive serotonin release assay or requires use of a non-heparin alternative anticoagulation strategy for cardiopulmonary bypass in the judgement of the Investigator.\n7. Patient is on durable MCS (e.g., LVAD or RVAD).\n8. Planned need for durable or temporary RVAD support concomitant with LVAD implant.\n9. Patient is on any form of pre-implant temporary MCS other than isolated LVAD support with an IABP.\n10. Patient is on any form of pre-implant temporary MCS with a serum lactate dehydrogenase greater than 2.5 times the upper limits of normal or with plasma free hemoglobin \\> 40 g\u002FdL.\n11. Patient has a history of organ transplantation.\n12. Patient has a mechanical aortic valve that may not be converted to a bioprosthetic valve at the time of VAD implant.\n13. Patient has a platelet count \\\u003C 50 k\u002Fµl.\n14. Patient has a history of confirmed untreated abdominal aortic aneurysm (AAA) \\> 5 cm in diameter.\n15. Patient has moderate or severe aortic insufficiency that will not be corrected during the VAD implant procedure.\n16. Patient has an uncontrolled systemic infection.\n17. Patient has a positive COVID 19 test within 21 days of study enrollment and at least one high risk feature including need for supplemental oxygen or ferritin \\>1000 ug\u002FL.\n18. Patient has severe end-organ dysfunction as evidenced by one or more of the following criteria:\n\n    1. Total bilirubin \\> 3.0 mg\u002FdL or cirrhosis confirmed by liver imaging or hemodynamic assessment with or without biopsy confirmation.\n    2. International normalized ratio (INR) ≥ 2.0 or PTT \\> 2.5 times control that is not related to anticoagulation therapy.\n    3. Glomerular filtration rate (GFR) \\\u003C 30 mL\u002F min\u002F1.73 m2 or need for renal replacement therapy.\n    4. Severe pulmonary arterial hypertension with a pulmonary vascular resistance (PVR) ≥ 8 Wood units that is not acutely reversible with pharmacologic intervention.\n    5. Severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen or an FEV1\u002FFVC \\\u003C 0.7 and FEV1 \\\u003C 40% predicted.\n    6. Mechanical ventilation for more than three days present at the time of study enrollment.\n    7. Documented history of pulmonary embolism or pulmonary infarct within 60 days of study enrollment.\n    8. History of stroke within 90 days of study enrollment or history of stroke with a mRS ≥ 3 at the time of study enrollment.\n    9. Symptomatic cerebrovascular disease and\u002For uncorrected carotid stenosis \\> 80%.\n    10. Significant peripheral vascular disease (PVD) accompanied by pain at rest or extremity ulceration.\n    11. Pre-albumin \\\u003C 15 mg\u002FdL and\u002For albumin \\\u003C 2.5 g\u002FdL.\n19. Patient has a non-cardiac comorbidity or illness that would limit survival to less than two years.\n20. Patient has a psychiatric disease or disorder, or irreversible cognitive dysfunction, and\u002For insufficient social support or a history of non-adherence with medical instructions that is likely to impair study compliance.\n21. Patient is participating in an interventional clinical trial that may impact or confound the results of the BrioVAD Trial.","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical investigation evaluates the safety and clinical performance of the BrioVAD Left Ventricular Assist System in patients with advanced, refractory left ventricular heart failure who require mechanical circulatory support.",[27,28],"Refractory Heart Failure","Cardiovascular Diseases (CVD)",[30,31],"BrioVAD System","Left Ventricular Assist Device","RECRUITING","2026-06-18",{"date":35,"type":36},"2026-06-22","ACTUAL",{"date":38,"type":36},"2026-06-01",{"date":40,"type":21},"2029-01-31",{"name":42,"class":43},"BrioHealth BV","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100506562","corheart-6-lvas-study-100506562","NCT05876000","Corheart 6 LVAS Study","Prospective Multi-Center Single-Arm Study for Evaluating the Corheart 6 Left Ventricular Assist System","Inclusion Criteria:\n\n* 1\\. Age ≥ 18 years and ≤ 75 years\n* 2\\. The patient has signed an Informed Consent Form\n* 3\\. Body Surface Area (BSA) ≥ 1.2 m\\^2\n* 4\\. New York Heart Association (NYHA) Class IV\n* 5\\. Left Ventricular Ejection Fraction (LVEF) ≤ 25%\n* 6\\. Despite the optimal medical management based on current guidelines, the patient must also meet one or more of the following:\n* a. Unable to exercise for HF,\n* or\n* if able to perform cardiopulmonary testing, with peak VO2 \\\u003C12 mL\u002Fkg\u002Fmin and\u002For \\\u003C 50% predicted value;\n* b. Progressive end-organ dysfunction (worsening renal and\u002For hepatic function, type II pulmonary hypertension, cardiac cachexia) due to reduced perfusion and not to inadequately low ventricular filling pressure (PCWP \\> 20 mmHg and SBP \\\u003C 90 mmHg or CI \\\u003C 2.0 L\u002Fmin\u002Fm2).\n* c. Impella or IABP assisted;\n* d. Inotrope dependent\u002Funable to wean from inotropes.\n\nExclusion Criteria:\n\n* 1\\. Heart failure who can be treated with other therapy options (e.g. CRT, CRT-D, etc.)\n* 2\\. Intolerance to anticoagulant or antiplatelet therapies or any other peri\u002Fpost-operative therapy the investigator will require based upon the patients' health status.\n* 3\\. Patient has known hypo or hyper coagulable states such as disseminated intravascular coagulation and heparin induced thrombocytopenia type II.\n* 4\\. Platelet count \\\u003C 100,000 x 10\\^3\u002FL (\\\u003C 100,000\u002Fml).\n* 5\\. Psychiatric disease\u002F disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and ventricular assist system management.\n* 6\\. Technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator.\n* 7\\. Presence of an active, uncontrolled infection.\n* 8\\. Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure:\n* a. Total bilirubin \\> 51.3 μmol\u002FL (3.0 mg\u002Fdl), ischemic hepatitis, or biopsy proven liver cirrhosis, or clinically Child-Pugh B and C score.\n* b. History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1\u002FFVC \\\u003C 0.7, or FEV1 \\\u003C 50% predicted.\n* c. Fixed pulmonary hypertension with a most recent PVR ≥ 8 Wood units that is unresponsive to pharmacologic intervention.\n* d. History of stroke within 180 days prior to enrollment, or a history of cerebrovascular disease with symptomatic (\\> 70%) carotid artery stenosis\n* e. Serum creatinine ≥ 265 μmol\u002FL (3.0mg\u002Fdl) or requiring dialysis.\n* f. Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration.\n* 9\\. Etiology of heart failure (HF) due to or associated with uncorrected thyroid disease, obstructive\u002F restrictive cardiomyopathy, pericardial disease, amyloidosis or giant cell myocarditis.\n* 10\\. Uncorrected moderate to severe aortic insufficiency without plans for correction during pump implant.\n* 11\\. History of confirmed, untreated abdominal aortic aneurysm (AAA) or thoracic aortic aneurysm (TAA) \\> 5 cm in diameter.\n* 12\\. Uncontrollable ventricular tachyarrythmias\u002F ventricular fibrillation (VF).\n* 13\\. STEMI \\\u003C2 weeks before planned implantation.\n* 14\\. Right ventricular failure as defined by one or more of the following:\n* a. severe depressed RV function in echocardiography\n* b. TAPSE \\\u003C 1.0 cm\n* c. CVP\u002FPCWP ratio \\> 0.63\n* 15\\. Planned Bi-VAD support prior to enrollment.\n* 16\\. Cardiac arrest with a history of resuscitation 1-month before inclusion, without full restoration of cognitive function.\n* 17\\. History of any organ transplant.\n* 18\\. Pre albumin \\\u003C 150 mg\u002FL, or Albumin \\\u003C 30g\u002FL (3 g\u002FdL).\n* 19\\. Any condition other than HF that could limit survival to less than 24 months.\n* 20\\. Positive pregnancy test if of childbearing potential.\n* 21\\. Lactating mothers.\n* 22\\. Participation in any other clinical investigation that is likely to confound study results or affect the study.\n* 23\\. Patients who have been placed in an institution by court order or by order of the authorities.","75 Years",{"count":53,"type":21},53,[24],"The primary objective of this study is to evaluate the safety and effectiveness of the Corheart 6 LVAS when used for the treatment of advanced left ventricular heart failure in a European population at 6 months post-implantation.\n\nThe secondary objective is to assess the long-term safety and effectiveness of Corheart 6 LVAS treatment.",[27],[58,59,60],"Advanced Heart Failure","Left Ventricular Assist System","Mechanical Circulatory Support","2026-01-06",{"date":63,"type":36},"2026-01-08",{"date":65,"type":36},"2024-05-14",{"date":67,"type":21},"2031-06-30",{"name":69,"class":43},"Shenzhen Core Medical Technology CO.,LTD.",11]